share_log

Piper Sandler Maintains Overweight on Biogen, Raises Price Target to $360

Piper Sandler Maintains Overweight on Biogen, Raises Price Target to $360

派珀·桑德勒維持對Biogen的增持,將目標股價上調至360美元
Benzinga ·  2023/06/01 09:18

Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $346 to $360.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論